Background: Persistence and adherence to treatment are considered efficacy outcomes
in psychiatric disorders. One of the best ways to improve these values in patients with psychiatric
disorders is to prefer Long-Acting Injectable (LAI) drugs to oral AP.
Objective: The objective of this study is to evaluate adherence, persistence and switching of antipsychotics
and compare in real life long-acting with oral formulations.
Materials and Methods: This pharmacological, observational, retrospective and non-interventional
study involved all patients of the ASL of Pescara treated in the front-line with AP in the period
between January 2011 and February 2019. Adherence was measured using the ratio between the
received daily dose and prescribed daily dose. Persistence to treatment with antipsychotics was
calculated as the daily difference between the beginning and end of treatment.
Results: We examined 840 patients treated with aripiprazole, 130 patients treated with paliperidone
and 925 patients treated with risperidone. Adherence was significantly better in long-acting formulations
with values of 0.89 (aripiprazole) and 0.82 (paliperidone and risperidone) than in oral formulations
with values of 0.78, 0.70 and 0.58, respectively (p> 0.999, p= 0.0091, p=< 0.0001). Threeyear
persistence curves relating to three study drugs did not show a statistically significant difference
(p = 0.3314). Persistence curves based on formulation have not shown a statistically significant
difference (p= 0, 4658, p=0, 4794, p=0, 2199 for ariprazolo, paliperidone and risperidone, respectively).
7% of patients were treated with aripiprazole, 12% of patients were treated with risperidone
and 28% of patients were treated with paliperidone switched therapy.
Conclusion: In all the drugs of present study, adherence values were better in LAI than in OA,
whereas no statistically significant difference was found in persistence values.